Example: Heart Attack

Clinical Trials on Melanoma, Experimental

Total 19 results

NCT00924001

Terminated

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Conditions: Melanoma; Malignant Melanoma; Melanoma, Experimental
NCT00513604

Completed

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Conditions: Melanoma; Malignant Melanoma; Melanoma, Experimental; Experimental Melanomas
NCT00846833

Completed

Haploidentical NK Cell Infusion in Malignant Melanoma

Conditions: Melanoma
NCT04700072

Not yet recruiting

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

Conditions: Melanoma
NCT04305041

Recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Conditions: Melanoma
NCT04305054

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Conditions: Melanoma
NCT04303169

Recruiting

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Conditions: Melanoma
NCT02723006

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

Conditions: Melanoma
NCT03068455

Active, not recruiting

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

Conditions: Melanoma
NCT02320058

Active, not recruiting

An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself

Conditions: Melanoma
NCT04674683

Recruiting

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Conditions: Unresectable or Metastatic Melanoma; Progressive Brain Metastasis
NCT03329846

Active, not recruiting

An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma

Conditions: Melanoma; Skin Cancer
NCT01065441

Completed

Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer

Conditions: Solid Tumors Stage II, Stage III and Stage IV; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Sarcoma; Non-small Cell Lung Cancer
NCT00972933

Completed

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

Conditions: Melanoma
NCT03693378

Active, not recruiting

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

Conditions: Pancreatic Ductal Adenocarcinoma; Familial Pancreatic Cancer; FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
NCT01106040

Completed

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Conditions: Breast Cancer; Melanoma
NCT02658890

Recruiting

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Conditions: Advanced Cancer; Melanoma; Non-Small Cell Lung Cancer
NCT02763761

Withdrawn

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Conditions: Renal Cell Carcinoma; Melanoma; Lung Cancer
NCT00068003

Enrolling by invitation

Harvesting Cells for Experimental Cancer Treatments

Conditions: Melanoma; Gastrointestinal Cancer; Metastatic Cancer; Breast Cancer; Non-Small-Cell Lung Cancer